Page 11 - Crispr Therapeutics News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Crispr therapeutics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Crispr Therapeutics Today - Breaking & Trending Today

CRISPR Therapeutics AG (NASDAQ:CRSP) CEO Samarth Kulkarni Sells 20,000 Shares of Stock

CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) CEO Samarth Kulkarni sold 20,000 shares of the stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $80.36, for a total transaction of $1,607,200.00. Following the transaction, the chief executive officer now directly owns 187,377 shares in the company, […] ....

Samarth Kulkarni , Fairfield Bush , Securities Exchange Commission , Therapeutics Company Profile , Blackrock Inc , Morgan Stanley , Us Bancorp , Needham Company , Cibc World Market Inc , York Mellon Corp , Get Free Report , Exchange Commission , Stock Down , New York Mellon Corp , Cibc World Market , World Market , Crispr Therapeutics , Nasdaq Crsp , Insider Trading , Nsider Trades ,

Want $1 Million in Retirement? Invest $250,000 in These 3 Stocks and Wait a Decade.

These stocks have what it takes to drive superior returns in the years to come. ....

Vertex Pharmaceuticals , Motley Fool Stock Advisor , Crispr Therapeutics , Treatment Options , Growth Stock , Ystic Fibrosis Therapy ,

What's Going On With Crispr Therapeutics Stock? - CRISPR Therapeutics (NASDAQ:CRSP)

Crispr Therapeutics shares are trading higher Thursday after Wolfe Research analyst Andy Chen initiated coverage on Crispr Therapeutics with a Peer Perform rating. Crispr Therapeutics' shares have risen nearly 37% over the past month following the FDA approval of Casgevy (exagamglogene autotemcel [exa-cel]), a CRISPR/Cas9 gene-edited cell therapy, for transfusion-dependent beta-thalassemia (TDT) in patients 12 years and older on Jan. 16. ....

Samarth Kulkarni , Crispr Therapeutics , Andy Chen , Wolfe Research , Peer Perform , Going On With Plug Power Stock , Benzinga Pro ,

Crispr Therapeutics Agrees to Sell $280 Million of Shares in Direct Offering

By Mary de Wet Crispr Therapeutics has entered an agreement to sell about $280 million of its common shares to a group of institutional investors in a. ....

Samarth Kulkarni , Chief Executive , Chairman Samarth , Mary De Wet , Article Normal , Biotechnology Services , Healthcare Life Sciences , Crispr Therapeutics , Life Sciences ,

Buy Rating Affirmed for Crispr Therapeutics with Increased Price Target Following EU Approval and Capital Boost

Analyst Silvan Tuerkcan of JMP Securities maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report), with a price target . ....

Silvan Tuerkcan , European Union , Analyst Silvan Tuerkcan , Crispr Therapeutics , Research Report , Sickle Cell Disease , Transfusion Dependent Thalassemia , Truist Financial , Tipranks Premium ,